Idiopathic inflammatory myopathies and the lung

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 216-238

  Lega, Jean Christophe ^a   Reynaud, Quitterie ^a   Belot, Alexandre ^a   Fabien, Nicole ^b   Durieu, Isabelle ^a   Cottin, Vincent ^a  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; PROSTACYCLIN; RITUXIMAB; SILDENAFIL; TACROLIMUS; TADALAFIL; TREPROSTINIL; BIOLOGICAL MARKER;

ADULT; ARTHRALGIA; ARTICLE; BED REST; BREATHING MUSCLE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; EMPHYSEMA; FEVER; HEART DISEASE; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC INFLAMMATORY MYOSITIS; INCLUSION BODY MYOSITIS; INFECTION; INTERSTITIAL LUNG DISEASE; JUVENILE; LUNG FIBROSIS; LUNG FUNCTION TEST; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYOSITIS; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMAPHERESIS; PLEURA DISEASE; PLEURA EFFUSION; PNEUMOMEDIASTINUM; PNEUMOTHORAX; POLYMYOSITIS; PREVALENCE; PULMONARY HYPERTENSION; RADIOLOGY; RAYNAUD PHENOMENON; THORAX DRAINAGE; ANIMAL; BLOOD; COMORBIDITY; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; LUNG; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; TIME;

ANIMALS; AUTOANTIBODIES; BIOMARKERS; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; MYOSITIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 84930435987     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00002015     Document Type: Article

References (177)

1. 1 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–347.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403–407.
3. Le Goff B, Cherin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61: 108–118.
4. Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2013; 73: 227–232.
5. Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, a etiology and survival. Eur Respir J 2013; 42: 1271–1282.
6. Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2014 [In press DOI: 10.1136/annrheumdis-2013-205127].
7. Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597–613.
8. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmunity Rev 2014; 13: 883–891.
9. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297–301.
10. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmunity Rev 2014; 13: 367–371.
11. Troyanov Y, Targoff IN, Payette MP, et al. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 2014; 93: 318–332.
12. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007; 19: 580–591.
13. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245–250.
14. Saketkoo LA, Ascherman DP, Cottin V, et al. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 2010; 6: 108–119.
15. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Rev 2012; 12: 210–217.
16. Sanner H, Aalokken TM, Gran JT, et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011; 70: 86–91.
17. Marie I, Menard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011; 41: 48–60.
18. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20: 513–528.
19. Lega JC, Cottin V, Fabien N, et al. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol 2010; 37: 1000–1009.
20. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314–324.
21. Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013; 40: 550–564.
22. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360–374.
23. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019–1038.
24. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134–153.
25. Targoff I. Aminoacyl-tRNA (other than histidyl) synthetase autoantibodies. In: Peter J, Shoenfeld Y, eds. Autoantibodies. Amsterdam, Elsevier Science 1996; pp. 36–45.
26. Gelpi C, Kanterewicz E, Gratacos J, et al. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996; 39: 692–697.
27. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006; 73: 646–654.
28. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993; 91: 2556–2564.
29. Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 1977; 59: 176–178.
30. Raijmakers R, Renz M, Wiemann C, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/ scleroderma overlap syndrome. Arthritis Rheum 2004; 50: 565–569.
31. D’Aoust J, Hudson M, Tatibouet S, et al. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 2014; 66: 1608–1615.
32. Marie I, Lahaxe L, Benveniste O, et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162: 337–344.
33. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–1576.
34. Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013; 15: 335–342.
35. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307–1315.
36. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290-797.
37. Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64: 1602–1610.
38. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014; 16: R138.
39. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807–1814.
40. Sugiura K, Muro Y, Akiyama M. Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol 2012; 67: e167–168.
41. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710–713.
42. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65: 2954–2962.
43. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
44. Gossez M, Levesque M, Khouatra C, et al. Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody. Eur Respir Rev 2015; 24: 370–372.
45. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100. French Canadian patients. Medicine (Baltimore) 2005; 84: 231–249.
46. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12. October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337–345.
47. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614–622.
48. Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14: 534–542.
49. Tani K, Tomioka R, Sato K, et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest 2007; 54: 295–302.
50. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44: 1282–1286.
51. Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010; 138: 1464–1474.
52. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233–241.
53. Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 25–41.
54. Kobayashi S, Higuchi K, Tamaki H, et al. Characteristics of juvenile dermatomyositis in Japan. Acta Paediatr Jpn 1997; 39: 257–262.
55. Adimulam S, Chinoy H, Edge K, et al. In adult idiopathic inflammatory myopathies (IIM), the HLA-DRB1null03-associated increased risk for developing anti-Jo-1 antibodies is exacerbated in smokers. Rheumatology 2009; 48: i25.
56. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8: R13.
57. Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010; 49: 1726–1733.
58. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32: 1719–1726.
59. Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65: 800–808.
60. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26: 1647–1654.
61. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147: 391–398.
62. Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341–1347.
63. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63: 53–59.
64. Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65: 1316–1324.
65. Gerfaud-Valentin M, Ahmad K, Piegay F, et al. Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies. Rev Mal Respir 2015; 31: 849–853.
66. Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology 2015 [In press DOI: 10.1093/rheumatology/keu385].
67. Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol 2014; 10: 728–739.
68. Cherin P, Herson S, Crevon MC, et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol 1996; 23: 1135–1142.
69. Benveniste O, Cherin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167: 3521–3529.
70. Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002; 129: 541–548.
71. Furuya T, Hakoda M, Tsuchiya N, et al. Immunogenetic features in 120. Japanese patients with idiopathic inflammatory myopathy. J Rheumatol 2004; 31: 1768–1774.
72. Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38: 259–266.
73. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661–662.
74. Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006; 55: 791–798.
75. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992; 35: 1211–1217.
76. Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992; 71: 327–336.
77. Rice GI, del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014; 46: 503–509.
78. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507–518.
79. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–1185.
80. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59: 677–685.
81. Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmunity Rev 2012; 11: 739–745.
82. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013; 107: 745–752.
83. Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008; 35: 260–269.
84. Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. Am J Roentgenol 1997; 169: 83–87.
85. Debray MP, Borie R, Revel MP, et al. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 2015; 84: 516–523.
86. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32: 58–64.
87. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 2006; 28: 1005–1012.
88. Meyer KC. The clinical utility of bronchoalveolar lavage in interstitial lung disease - is it really useful? Expert Rev Respir Med 8: 133–135.
89. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585–596.
90. Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101: 1761–1769.
91. Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136: 23–30.
92. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273–284.
93. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38: 383–392.
94. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52: 2439–2446.
95. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46: 124–130.
96. Ideura G, Hanaoka M, Koizumi T, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007; 101: 1406–1411.
97. Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008; 35: 254–259.
98. Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48: 968–971.
99. Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012; 106: 581–587.
100. Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49: 361–369.
101. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62: 1496–1501.
102. Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63: 3439–3447.
103. Cavagna L, Caporali R, Abdi-Ali L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 2013; 40: 484–492.
104. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187: 201–206.
105. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmunity Rev 2011; 11: 6–13.
106. Labirua-Iturburu A, Selva-O’Callaghan A, Martinez-Gomez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013; 31: 436–439.
107. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacol 2000; 47: 85–118.
108. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640–646.
109. Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29: 1499–1502.
110. Kalinova D, Rashkov R, Kolarov ZI. Tumor-associated myositides. Rheumatology 2009; 17: 18–25.
111. Hervier B, Devilliers H, Benveniste O. Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2013; 72: e18.
112. Caldwell IW, Aitchison JD. Pulmonary hypertension in dermatomyositis. Br Heart J 1956; 18: 273–276.
113. Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. Chest 1981; 79: 105–107.
114. Foris V, Kovacs G, Matucci-Cerinic M, et al. PL-7 positive antisynthetase syndrome and pulmonary hypertension. J Rheumatol 2013; 40: 1777–1779.
115. Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135: 1550–1556.
116. Honma F, Shio K, Monoe K, et al. Primary biliary cirrhosis complicated by polymyositis and pulmonary hypertension. Intern Med 2008; 47: 667–669.
117. Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. Arthritis Care Res (Hoboken) 2010; 62: 425–429.
118. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9: R78.
119. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: Suppl., D109–D116.
120. Cavagna L, Prisco E, Montecucco C, et al. Pulmonary arterial hypertension in antisynthetase syndrome: comment on the article by Chatterjee and Farver. Arthritis Care Res (Hoboken) 2011; 63: 633–634.
121. Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus 2009; 18: 1006–1010.
122. Yaqub S, Moder KG, Lacy MQ. Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 2004; 79: 687–689.
123. Mariette X, Brenot F, Brouet JC. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjogren’s syndrome and polymyositis. J Rheumatol 1994; 21: 772–773.
124. Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182–189.
125. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151–157.
126. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med 2012; 18: 418–427.
127. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586–593.
128. Girard N, Marchand-Adam S, Naccache JM, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47. Western patients. J Thorac Oncol 2014; 9: 1162–1170.
129. Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63: 295–304.
130. Chen L, Hu Y, Yao Y, et al. Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease. Zhonghua Er Ke Za Zhi 2012; 50: 465–469.
131. Dogra S, Suri D, Shah R, et al. Spontaneous pneumomediastinum: a rare complication of juvenile dermatomyositis. Int J Rheum Dis 2012; 15: e131–e133.
132. Ye Q, Zhang L, Tian X, et al. Exacerbation of pneumomediastinum after air travel in a patient with dermatomyositis. Aviat Space Environ Med 2011; 82: 734–736.
133. Cozzani E, Cinotti E, Felletti R, et al. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol 2013; 35: 687–692.
134. Onishi S, Ono F, Hasegawa H, et al. Pneumomediastinum and massive subcutaneous emphysema associated with dermatomyositis. Intern Med 2012; 51: 3449–3450.
135. Rodrigues AJ, Jacomelli M, Scordamaglio PR, et al. Spontaneous pneumomediastinum associated with laryngeal lesions and tracheal ulcer in dermatomyositis. Rev Bras Reumatol 2012; 52: 796–799.
136. Kartik S, Bhakuni DS, Shanmuganandan K. Continuous diaphragm sign in amyopathic dermatomyositis. Joint Bone Spine 2013; 80: 102–103.
137. Saraya T, Tanaka Y, Ohkuma K, et al. Massive tension pneumomediastinum. Intern Med 2012; 51: 677.
138. Kono H, Inokuma S, Nakayama H, et al. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59: 372–376.
139. Sandhya P, Keshava SN, Danda D, et al. Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 2012; 32: 1415–1419.
140. Powell C, Kendall B, Wernick R, et al. A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease. Chest 2007; 132: 1710–1713.
141. Lee MA, Hutchinson DG. Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab. Clin Rheumatol 2010; 29: 945–946.
142. Mogulkoc N, Kabasakal Y, Ekren PK, et al. An unusual presentation of anti-Jo-1 syndrome, mimicking lung metastases, with massive pleural and pericardial effusions. J Clin Rheumatol 2006; 12: 90–92.
143. Derk CT, Sandorfi N, Curtis MT. A case of anti-Jo1 myositis with pleural effusions and pericardial tamponade developing after exposure to a fermented Kombucha beverage. Clin Rheumatol 2004; 23: 355–357.
144. Miyata M, Fukaya E, Takagi T, et al. Two patients with polymyositis or dermatomyositis complicated with massive pleural effusion. Intern Med 1998; 37: 1058–1063.
145. Marie I, Hachulla E, Cherin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53: 155–165.
146. Ikeue T, Ueshima K, Watanabe S, et al. Pneumonia caused by Nocardia nova. Nihon Kokyuki Gakkai Zasshi 2001; 39: 492–497.
147. La Civita L, Battiloro R, Celano M. Nocardia pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy. J Rheumatol 2001; 28: 215–217.
148. Shah NM, Balakrishnan C, Mangat GK, et al. Pulmonary nocardial infection and pseudomonas infection of the tongue in a patient with dermatomyositis. J Assoc Physicians India 2001; 49: 850–851.
149. Lonneux M, Nolard N, Philippart I, et al. A case of lymphocytic pneumonitis, myositis, and arthritis associated with exposure to Aspergillus niger. J Allergy Clin Immunol 1995; 95: 1047–1049.
150. Kaiser L, Huguenin T, Lew PD, et al. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188–194.
151. Lynch JP 3rd, Schaberg DR, Kissner DG, et al. Cryptococcus laurentii lung abscess. Am Rev Respir Dis 1981; 123: 135–138.
152. Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66: 1245–1247.
153. Kasifoglu T, Korkmaz C, Ozkan R. Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis. Clin Rheumatol 2006; 25: 731–733.
154. Nishi K, Myoh S, Bandoh T, et al. An autopsy case of dermatomyositis associated with interstitial pneumonia probably due to cytomegalovirus infection. Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30: 1975–1980.
155. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 2013; 51: 260–277.
156. Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42: 282–291.
157. Chen YJ, Wu CY, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12: R70.
158. Kuo CF, See LC, Yu KH, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011; 165: 1273–1279.
159. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Brit J Cancer 2001; 85: 41–45.
160. Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 2013; 169: 838–847.
161. Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9: e94128.
162. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–3689.
163. Kasuya A, Hamaguchi Y, Fujimoto M, et al. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody. Acta Derm Venereo 2013; 93: 715–716.
164. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523–532.
165. Maclean J, Singh RB, Sayeed ZA. Polymyositis presenting with respiratory failure. Indian J Chest Dis Allied Sci 2011; 53: 229–231.
166. Suresh E, Wimalaratna S. Proximal myopathy: diagnostic approach and initial management. Postgrad Med J 2013; 89: 470–477.
167. Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 2010; 31: 501–512.
168. Péter A, Balogh Á, Szilágyi S, et al. Echocardiographic abnormalities in new-onset polymyositis/dermatomyositis. J Rheumatol 2015; 42: 272–281.
169. Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35–42.
170. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15: 168–178.
171. Denbow CE, Lie JT, Tancredi RG, et al. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979; 22: 1088–1092.
172. Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28: 249–255.
173. Zhang L, Wang GC, Ma L, et al. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 2012; 35: 686–691.
174. Danieli MG, Gambini S, Pettinari L, et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmunity Rev 2014; 13: 1048–1054.
175. Agrawal CS, Behari M, Shrivastava S, et al. The heart in polymyositis-dermatomyositis. J Neurol 1989; 236: 249–250.
176. Ungprasert P, Suksaranjit P, Spanuchart I, et al. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014; 44: 63–67.
177. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheum 1996; 14: 373–379.